Provided by Tiger Trade Technology Pte. Ltd.

Harmony Biosciences Holdings, Inc.

42.02
-0.7200-1.68%
Post-market: 42.020.00000.00%19:30 EDT
Volume:3.82M
Turnover:161.54M
Market Cap:2.45B
PE:13.59
High:43.27
Open:42.57
Low:41.90
Close:42.74
52wk High:43.49
52wk Low:25.52
Shares:58.24M
Float Shares:50.80M
Volume Ratio:3.40
T/O Rate:7.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.09
EPS(LYR):2.71
ROE:20.46%
ROA:11.62%
PB:2.45
PE(LYR):15.51

Loading ...

Harmony Biosciences : Mizuho Raises Target Price to $51 from $50

THOMSON REUTERS
·
Aug 03

Harmony Biosciences (HRMY) Stock Looks Below Fair Value On Earnings

Simply Wall St.
·
Aug 02

Earning Preview: Harmony Biosciences Holdings, Inc. this quarter’s revenue is expected to increase by 22.01%, and institutional views are bullish

Earnings Agent
·
Jul 29

Harmony Biosciences Interim Principal Financial Officer Stephen Mollichella Files Initial Beneficial Ownership Statement

Reuters
·
Jul 23

Harmony Biosciences to Report Q2 Results Before US Market Open, Host Conference Call and Webcast

Reuters
·
Jul 21

Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Alkermes (ALKS)

TIPRANKS
·
Jul 20

Harmony Biosciences Posts Record Q2 WAKIX Revenue

TIPRANKS
·
Jul 17

Harmony Biosciences Price Target Maintained with a $55.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 17

Harmony Biosciences: Strong WAKIX Outperformance and Pipeline Catalysts Support Buy Rating and Unchanged $55 Price Target

TIPRANKS
·
Jul 17

Harmony Biosciences Expects Higher Q2 Wakix Revenue; CFO Glenn Reicin Steps Down

MT Newswires Live
·
Jul 16

Harmony Biosciences Reaffirms 2026 Net Revenue Outlook of $1 Billion-$1.04 Billion

Reuters
·
Jul 16

GUIDANCE: (HRMY) Harmony Biosciences Expects 2026 Net Revenue Range $1.0B - $1.04B, vs. FactSet Est of $1.01B

MT Newswires Live
·
Jul 16

Harmony Biosciences CFO Reicin Steps Down, Names Mollichella Interim Finance Chief

Reuters
·
Jul 16

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-year 2026 Revenue Guidance, and Announces CFO Transition

THOMSON REUTERS
·
Jul 16

Harmony Biosciences - Reiterates Fy2026 Net Product Revenue Guidance of $1 Bln to $1.04 Bln

THOMSON REUTERS
·
Jul 16

Harmony Biosciences - Announces Preliminary Q2 2026 Wakix Revenue of Approx $261 Mln, up 30% Year over Year

THOMSON REUTERS
·
Jul 16

Harmony Biosciences - Appoints Stephen Mollichella as Interim Principal Financial Officer

THOMSON REUTERS
·
Jul 16

Harmony Biosciences - CFO Glenn Reicin Steps Down Effective July 16, 2026

THOMSON REUTERS
·
Jul 16

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 08

Harmony Biosciences is Maintained at Hold by Deutsche Bank

Dow Jones
·
Jul 01